Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromid
Updated: Jan 31
Commercial launch of ECCLOCK® in Japan currently underway by Development Partner, Kaken Pharmaceutical
111921 Brickell Biotech Announces Public
.
Download • 91KB
